This study is about a new drug called **cemiplimab**. It's being tested on two types of skin cancer: *Cutaneous Squamous Cell Carcinoma (CSCC)* and *Basal Cell Carcinoma (BCC)*. The goal is to see if cemiplimab is safe and how it affects the body. In the first part, people got different doses of the drug once a week for 12 weeks. Researchers want to know what side effects might happen, how the drug affects the tumor, and how much of it is in the blood at different times. To join, you need to have certain types of CSCC or BCC and be in good enough health according to the Eastern Cooperative Oncology Group (ECOG) performance status. You cannot join if you have certain other health issues, had some specific treatments before, or if you had a COVID-19 vaccine recently.

• The study lasts for 12 weeks with weekly visits.
• Participants may experience side effects from the drug.
• You must meet specific health criteria to join.